Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 40Breast Neoplasms 23Gliosarcoma 22Esophageal Neoplasms 21Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Rectal Neoplasms 13Glioma 13Brain Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 12Lung Neoplasms 11Head and Neck Neoplasms 11Melanoma 10Astrocytoma 10Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Central Nervous System Neoplasms 8Stomach Neoplasms 7Lymphoma, Follicular 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Adenocarcinoma Of Esophagus 6Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lymphoma 5Carcinoma 5Burkitt Lymphoma 5

Interventions

Amifostine 12Cisplatin 10Radiotherapy 8Etoposide 8Cyclophosphamide 5Paclitaxel 4Filgrastim 4Gemcitabine 3Cytarabine 3Carboplatin 3denileukin diftitox 2apatinib 2Vincristine 2Pyridoxine 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2Doxorubicin 2Dexamethasone 2Chemotherapy, Adjuvant 2Bleomycin 2uridine triacetate 1sargramostim 1peginterferon alfa-2b 1pegfilgrastim 1pegaspargase 1eribulin 1camrelizumab 1Vitamin E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × Radiation × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡